Purinergic pathways and their clinical use in the treatment of acute myeloid leukemia

分享到

Link by DOI

作者单位: Affiliations ¹ Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. ² Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. wangnadoris@12 com.

关键词: Acute myeloid leukemia Adenosine CD39 CD73 Clinical application Mechanism studies.

摘要: Despite the use of various therapies such as hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy , the prognosis of patients with acute myeloid leukemia is still generally poor. However, immunotherapy is currently a hot topic in the treatment of hematological tumors. Extracellular adenosine triphosphate can be converted to adenosine diphosphate via CD39, and ADP can be converted to adenosine via CD73, which can bind to P1 and P2 receptors to exert immunomodula...更多; Despite the use of various therapies such as hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy , the prognosis of patients with acute myeloid leukemia is still generally poor. However, immunotherapy is currently a hot topic in the treatment of hematological tumors. Extracellular adenosine triphosphate can be converted to adenosine diphosphate via CD39, and ADP can be converted to adenosine via CD73, which can bind to P1 and P2 receptors to exert immunomodulatory effects. Research on the mechanism of the purinergic signaling pathway can provide a new direction for the treatment of AML, and inhibitors of this signaling pathway have been discovered by several researchers and gradually applied in the clinic. In this paper, the mechanism of the purinergic signaling pathway and its clinical application are described, revealing a new target for the treatment of AML and subsequent improvement in patient prognosis.收起

列表公用js 卡片页统计

看了本文的还看了